This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Michael Bigby, MD; Kenneth A. Arndt, MD

JAMA. 1985;254(16):2283-2286.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

For the past 18 months, considerable attention has been focused on the use of retinoids, topical minoxidil, cultured epidermal cells, and nonsteroidal antiinflammatory drugs (NSAIDs) to treat a variety of skin diseases. The therapeutic uses and toxicity of the retinoids continue to dominate the attention of dermatologists. Application of minoxidil appears to be a relatively safe and effective way to induce hair growth in some individuals with androgenetic alopecia or alopecia areata. The dramatic effectiveness of cultured epidermal cells in covering burn wounds in two severely burned children highlighted a decade of achievement in the ability to grow human epidermal cells in culture.¹ Nonsteroidal anti-inflammatory drugs, which alter arachidonic acid metabolism, may be useful in treating hyperproliferative and inflammatory skin diseases, but produce varied adverse cutaneous reactions.

Since the introduction of isotretinoin (13-cis-retinoic acid) into the US market in September 1982, for the treatment of nodulocystic acne . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?